Comparing of BioDelivery Sciences International Inc. (BDSI) and Verona Pharma plc (NASDAQ:VRNA)

As Biotechnology companies, BioDelivery Sciences International Inc. (NASDAQ:BDSI) and Verona Pharma plc (NASDAQ:VRNA) are our subject to compare. And more specifically their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioDelivery Sciences International Inc. 50.12M 6.43 55.57M -0.93 0.00
Verona Pharma plc N/A 0.00 N/A -2.34 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for BioDelivery Sciences International Inc. and Verona Pharma plc.

Profitability

Table 2 shows BioDelivery Sciences International Inc. and Verona Pharma plc’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
BioDelivery Sciences International Inc. -110.87% -256.9% -55.9%
Verona Pharma plc 0.00% 0% 0%

Analyst Recommendations

BioDelivery Sciences International Inc. and Verona Pharma plc Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioDelivery Sciences International Inc. 0 0 1 3.00
Verona Pharma plc 0 0 0 0.00

Insider & Institutional Ownership

Institutional investors owned 54% of BioDelivery Sciences International Inc. shares and 64.53% of Verona Pharma plc shares. Insiders owned roughly 1.7% of BioDelivery Sciences International Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioDelivery Sciences International Inc. -1.64% -4.77% 25.96% 23.79% 30.55% 21.69%
Verona Pharma plc -3.49% -10.97% -10.82% -34.55% -24.59% -11.13%

For the past year BioDelivery Sciences International Inc. has 21.69% stronger performance while Verona Pharma plc has -11.13% weaker performance.

Summary

On 6 of the 10 factors BioDelivery Sciences International Inc. beats Verona Pharma plc.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.